OGphoto/iStock via Getty Images The combination of AstraZeneca's (NASDAQ:AZN) Imfinzi (durvalumab) + the company's experimental CTLA-4 inhibitor tremelimumab led to a clinically meaningful ...
网页链接OGphoto/iStock via Getty Images The combination of AstraZeneca's (NASDAQ:AZN) Imfinzi (durvalumab) + the company's experimental CTLA-4 inhibitor tremelimumab led to a clinically meaningful ...
网页链接
精彩评论